...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

narmac

Rank: Vice President [?]

Points: 3973 [?]

Votes: 36 Score: 3.0 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: AACR 2019

in response to

Re: AACR 2019

BearDownAZ

posted on Feb 28, 2019 11:46AM

https://www.researchgate.net/publicationrs

Abstract P3-06-07: The BET bromodomain inhibitors ZEN-3694 and ZEN-3309 targets several mechanisms of resistance to endocrine therapies in preclinical models of ER+ breast cancers

2 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply